TARRYTOWN, N.Y., Dec. 3, 2021 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in
a virtual fireside chat at the H.C. Wainwright & Co. event –
Unlocking the Full Potential of RNAi With World-Class Novel Target
Identification: Regeneron Genomics and Alnylam's RNAi Platform
Collaboration Update – at 2:00 p.m. ET on Monday, December 6, 2021.
Aris Baras, M.D., Senior Vice
President at Regeneron and Head of the Regeneron Genetics Center,
will participate on behalf of Regeneron.
The session may be accessed from the "Investors &
Media" page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations. A replay
of the webcast will be archived on the Company's website for at
least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company
that invents life-transforming medicines for people with serious
diseases. Founded and led for over 30 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to nine
FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
Contact Information:
Investor
Relations
Mark
Hudson
914.847.3482
mark.hudson@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-to-participate-in-hc-wainwright--co-virtual-event-301437162.html
SOURCE Regeneron Pharmaceuticals, Inc.